Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy
Clinical trial NCT04466137 · COMPLETED
Trial details
- NCT number
- NCT04466137
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-16
- Primary completion
- 2021-06-24
- Enrollment
- 398
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.